Skip to main content

Silence Therapeutics plc

SLN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001479615

No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.

Other share classesSLNCF

Q3 2022 vs. Q2 2022

How the institutions holding Silence Therapeutics plc changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of SLN: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders2529+4
Shares10.4M18.7M+8.29M (+80.0%)
Value$116.4M$183.4M+$67.0M (+57.6%)

New holders (7)

Institutions that held Silence Therapeutics plc at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to SLN in Q3 2022
InstitutionSharesValue% of portfolio
Lombard Odier Asset Management (Europe) Ltd3,219,400$32.3M1.68%
TCG Crossover Management, LLC2,104,875$21.1M6.34%
Aquilo Capital Management, LLC1,263,125$12.7M5.33%
Woodline Partners LP115,120$1.16M0.02%
Millennium Management LLC14,557$144.0K0.00%
Geode Capital Management, LLC13,177$130.0K0.00%
Cubist Systematic Strategies, LLC500$5.00K0.00%

Sold out (3)

Institutions that held Silence Therapeutics plc at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of SLN in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Consonance Capital Management LP634,270$7.52M
Bellevue Group AG30,483$361.0K
Tower Research Capital LLC (TRC)120$1.00K